IRIS
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.001
Totale 4.001
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.001
Totale 4.001
Salva come PNG Salva come JPEG
Città #
Genova 3.005
Rapallo 536
Genoa 448
Bordighera 12
Totale 4.001
Salva come PNG Salva come JPEG
Nome #
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 138
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 127
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 124
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 120
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 119
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 117
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 116
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 114
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 110
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 109
The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. 105
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 103
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 102
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 101
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 100
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 99
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 91
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 89
Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. 88
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 84
Treatment of juvenile idiopathic arthritis: what's new? 83
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry 81
American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus 80
The PRINTO juvenile dermatomyositis trial - Authors' reply 79
Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative 78
Treating juvenile idiopathic arthritis to target: Recommendations of an international task force 78
Current and future perspectives in the management of juvenile idiopathic arthritis 75
Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study 74
Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus 73
The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry 73
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 69
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: Results of a multicentre, double-blind, randomised-withdrawal trial 69
The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry 69
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 67
Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study 66
An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA) 65
Current medical treatments for juvenile idiopathic arthritis 64
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 59
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials 58
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 57
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: Results of a phase 1, open-label, multicenter study 55
Extrapolation or controlled trials in paediatrics: The current dilemma 54
International consensus for a definition of disease flare in lupus 54
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 53
Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study 52
A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis 50
Development and testing of reduced versions of the MMT-8 in juvenile dermatomyositis 46
Disease activity, overweight, physical activity and screen time in a cohort of patients with juvenile idiopathic arthritis 41
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: Post hoc radiographic analysis from two randomized controlled trials 41
Preface 34
Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis 29
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group 29
Outcome Scores in Pediatric Rheumatology 23
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 14
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 13
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial 11
Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers 8
Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study 2
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 2
Paediatric rheumatologists do not score the physician's global assessment of juvenile idiopathic arthritis disease activity in the same way 2
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 1
Totale 4.187
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.254
article - articoli 14.254
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.508
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019159 0 0 0 0 0 0 0 0 0 0 88 71
2019/20201.431 108 42 20 91 117 143 233 138 153 203 133 50
2020/2021605 16 57 47 75 24 30 72 60 31 110 19 64
2021/2022667 65 32 30 56 14 62 19 136 61 69 31 92
2022/2023651 62 77 8 47 118 81 16 41 102 8 83 8
2023/2024353 38 47 13 58 44 67 21 30 18 17 0 0
Totale 4.187